|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide, KLH conjugated, corresponding to the residues L(419) Q F H R G S R A Q S F L Q T E T S V I(438) of human VPAC2 receptor.|
|Storage buffer||whole serum|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:500|
|Western Blot (WB)||1:250|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
PA3-114 detects VPAC2 Receptor in human samples.
PA3-114 has been successfully used in Western blot, immunocytochemistry and immunohistochemistry procedures. By Western blot, this antibody detects an ~50-65 kDa protein representing VPAC2 Receptor in human samples. In immunohistochemistry, VPAC2 receptor immunoreactivity is predominantly localized to neuroendocrine cells.
PA3-114 immunogen is a synthetic peptide, conjugated to KLH, corresponding to the residues L(419) Q F H R G S R A Q S F L Q T E T S V I(438) of human VPAC2 receptor.
The Vasoactive Intestinal Polypeptide Receptor 2 (VPAC2) is a member of a family of three G-protein coupled receptors which mediate VIP (vasoactive intestinal peptide) and PACAP (pituitary adenlyate cyclase activating peptide) function in a variety of tissues. Together, the VPAC1 and VPAC2 receptors compose a subtype of the VIP receptor. Expression of the VIP and PACAP receptors has been linked to the presence of human tumors.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Atypical nuclear localization of VIP receptors in glioma cell lines and patients.
PA3-114 was used in immunocytochemistry, immunohistochemistry - paraffin section, and western blot to study the expression and the nuclear localization of VPAC1 and VPAC2 in glioma
|Barbarin A,Séité P,Godet J,Bensalma S,Muller JM,Chadéneau C||Biochemical and biophysical research communications (454:524)||2014|